Department of Respiratory Medicine, Xiangya Hospital (Key Cite of National Clinical Research Center for Respiratory Disease), Central South University, Changsha, Hunan, 410008, PR China.
Department of Respiratory Medicine, Xiangya Hospital (Key Cite of National Clinical Research Center for Respiratory Disease), Central South University, Changsha, Hunan, 410008, PR China.
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):457-464. doi: 10.1016/j.bbrc.2018.11.061. Epub 2018 Nov 17.
Recent studies have demonstrated that exosomal miRNAs mediate as intercellular bio-messengers of drug resistance in lung cancer. Our objective was to investigate whether exosomes derived from gefitinib resistant non-small cell lung cancer cells could confer resistance to its recipient cells. Exosomes were successfully isolated by ultracentrifugation and exosomes morphologies and sizes were determined by transmission electron microscopy and dynamic light scattering analysis. Fluorescent PKH-67 labeled exosomes derived from PC-9GR cells could be taken up and internalized by PC-9 cells. CCK8 measurement showed that PC-9GR-derived exosomes could confer gefitinib resistance in PC-9 cells. MiRNA-214 was upregulated in gefitinib resistant PC-9GR cells and its derived exosomes by qPCR analysis. Inhibition of exosomal miR-214 with antagomir reversed gefitinib resistance conferred by PC-9GR-derived exosomes in vitro, which was confirmed by flow cytometry analysis and westernblot of apoptotic protein (caspase-3, caspase-3 cleaved, bax) and anti-apoptotic protein (bcl-2). Finally, exosomes enriched with miR-214 antagomir was further confirmed to reverse gefitinib resistance in vivo. Our results are the first to show that exosomes derived from gefitinib-resistant PC-9GR cells could transfer resistance to its recipient sensitive PC-9 cells, which might be mediated by exosomal transfer of miR-214.
最近的研究表明,外泌体 miRNAs 作为肺癌耐药性的细胞间生物信使。我们的目的是研究来自吉非替尼耐药的非小细胞肺癌细胞的外泌体是否可以赋予其受体细胞耐药性。通过超速离心成功分离出外泌体,并通过透射电子显微镜和动态光散射分析确定外泌体的形态和大小。荧光标记的 PKH-67 标记的源自 PC-9GR 细胞的外泌体可以被 PC-9 细胞摄取和内化。CCK8 测量表明,PC-9GR 衍生的外泌体可以在 PC-9 细胞中赋予吉非替尼耐药性。qPCR 分析显示,吉非替尼耐药的 PC-9GR 细胞及其衍生的外泌体中 miR-214 上调。用反义寡核苷酸抑制外泌体 miR-214 可逆转 PC-9GR 衍生的外泌体在体外赋予的吉非替尼耐药性,这通过流式细胞术分析和凋亡蛋白(caspase-3、caspase-3 切割、bax)和抗凋亡蛋白(bcl-2)的 Western blot 得到证实。最后,进一步证实富含 miR-214 反义寡核苷酸的外泌体可在体内逆转吉非替尼耐药性。我们的研究结果首次表明,来自吉非替尼耐药的 PC-9GR 细胞的外泌体可以将耐药性转移给其受体敏感的 PC-9 细胞,这可能是通过外泌体转移 miR-214 介导的。